Helicobacter pylori nanoparticles as a potential treatment of conventional multiple sclerosis

Medical Hypotheses

Volumn 70, Issue 6, 2008, Pages 1223-

  Pezeshki, Mohammad Zakaria ^a   Zarrintan, Sina ^a   Zarrintan, Mohammad Hossein ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; PROBIOTIC AGENT;

DRUG DELIVERY SYSTEM; ETHNICITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; JAPANESE; LETTER; MULTIPLE SCLEROSIS; PREVALENCE; PRIORITY JOURNAL;

DRUG CARRIERS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; NANOPARTICLES;

HELICOBACTER PYLORI;

EID: 42749091150     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.12.008     Document Type: Letter

References (5)

1. Pender M.P., and Greer J.M. Immunology of multiple sclerosis. Curr Allergy Asthma Rep 7 (2007) 285-292
2. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 23 (2005) 683-747
3. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2 (2003) 117-127
4. Li W., Minohara M., Su J.J., et al. Helicobacter pylori infection is a potential protective factor against conventional multiple sclerosis in the Japanese population. J Neuroimmunol 184 (2007) 227-231
5. Kingsley J.D., Dou H., Morehead J., et al. Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol 1 (2006) 340-350